Replies to post #404111 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

No they are not. The funds to fund the development of Sawston go into the asset that belongs to NWBO. That is a false assertion. The capital that goes to creating and marketing Advent is from the investors in Advent. The cost of labor up front, hiring, and all of the benefits or other inducements all come from other investors.

NWBO does not have these people on its payroll. The payment for building out Sawston is the cost of construction, which we know uses specialized other third-parties mentioned in the PR’s and would be the same no matter who was paying them, and then the costs of Advent plus 15% for managing the process as the operations and facilities manager.

These notions that get bandied about are pure false speculation and if they were true you’d be alleging crimes and looting, which you can easily go to the SEC fr but their accountants would likely note the looting in their certified accounting statements, unless they are involved too…

And what exactly monies are they looting to give to Advent? This company is not rolling in money. That is why this is being done the way it is being done. It is more efficient from a capital perspective and requires less monies up front.

But Advent does not own anything they are building. There is some symbiotic opportunity born of two companies with limited but complimentary resources, they have the manpower, labor and expertise and NWBO has the facility for the factory to be built. Adven does not have a factory or facility, but for now, to lower the start-up costs for NWBO, they can contract for manufacturing gigs in the large and unused space before NWBO is fully commercially operational, upon approval by NWBO, and the revenues no doubt will be discussed at that time of proposal. The unused but necessarily highly maintained factory will be an incubator for all the other companies that would efficiently share in the otherwise outrageous cost of maintaining an commercially operational facility with all of the employees that requires in payroll.

[ATLnsider]

hankmanhub, I am going to repeat some of what I said earlier. Most of that money that NWBio has spent to buildout the Sawston facility, is on NWBio’s balance sheet as assets. Some of it is under Plant, Property & Equipment (PP&E), some under Construction in Progress, and some under Right -of-Use asset.

This is “much ado about nothing”. All of these assets are for the benefit of NWBO shareholders. NWBio own all of the Sawston equipment, and leasehold improvements in that facility, That includes all of the clean rooms. Cognate and Advent are only “a means to an end”. The primary reasons Cognate was started were:

(1) To help NWBio fulfill the FDA’s and Health Canada’s requirement to have licensed and approved GMP manufacturing capabilities to complete the DCVax-L Phase III clinical trial.

(2) Convince the FDA and Health Canada that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the US and Canada.

(3) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, including Big Pharma

The primary reasons Advent was started were:

(1) Convince the EMA and MHRA that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the UK, Germany and the rest of the EU.

(2) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, in Europe including Big Pharma.

Both Cognate and Advent have served, and are continuing to serve their purpose. Both Cognate and Advent have created a lot of NWBO value and gains for NWBO shareholders. It is unfortunate that some NWBO shareholders don’t acknowledge or understand these facts.

I, personally prefer that NWBio continue to focus on becoming a high margin, highly profitable biotech, by focusing on exploiting and maximizing the worldwide value of the DCVax-L and DCVax Direct vaccine platform, that has the potential to treat all or most solid tumor cancers, both operable and inoperable.

I am not interested in NWBio focusing on a lower margin, more capital intensive and more labor intensive industry, like becoming a CDMO.